Loading...
•
Jun 30, 2023
Sangamo Q2 2023 Earnings Report
Reported business highlights and financial results for the second quarter of 2023.
Key Takeaways
Sangamo Therapeutics reported a net loss of $114.5 million for Q2 2023, compared to a net loss of $43.2 million for the same period in 2022. The increase in net loss was primarily due to higher non-cash charges relating to impairment of indefinite-lived intangible assets and a decrease in revenues.
Announced research evaluation and option agreement with Prevail Therapeutics for novel engineered cerebrospinal fluid-administered capsids.
Announced research evaluation and option agreement with Chroma Medicine to explore zinc finger proteins (ZFPs) for epigenetic editing.
Received U.S. FDA Fast Track Designation for isaralgagene civaparvovec for Fabry disease.
Phase 3 AFFINE trial of giroctocogene fitelparvovec for hemophilia A continues to progress, with pivotal data read-out expected in mid-2024.
Forward Guidance
Sangamo estimates GAAP operating expenses to be in the range of $378 million to $398 million and non-GAAP operating expenses to be in the range of $240 million to $260 million for 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...